[6-K] Nanobiotix S.A. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Nanobiotix S.A. reports that trading of its ordinary shares on Euronext Paris is being temporarily halted at the company’s request. The halt is linked to a previously announced global equity financing that combines a U.S. public offering of American Depositary Shares with an international offering of ordinary shares and pre-funded warrants to qualified investors outside the United States and Canada.

The pause is intended to allow final allocation to investors and announcement of pricing for this global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, at about 3:30 p.m. Paris time, which corresponds to 9:30 a.m. in New York.

Insights

Biotech capital markets analyst

Nanobiotix pauses Paris trading while it prices a cross-border equity raise.

Nanobiotix is coordinating a global equity financing that includes a U.S. public offering of ADSs and an international offering of ordinary shares and pre-funded warrants to qualified investors. The trading halt on Euronext Paris helps synchronize pricing and allocations across markets.

The filing does not disclose offering size, price, or use of proceeds, so the economic impact cannot yet be assessed. Actual dilution and capital raised will depend on final terms of the global offering, which the company plans to announce once allocations are confirmed and pricing is set on May 21, 2026.

Key Figures

Trading halt start time: 9:00 a.m. CEST Expected Paris trading resumption: 3:30 p.m. Corresponding New York time: 9:30 a.m.

3 metrics

Trading halt start time 9:00 a.m. CEST Opening of Euronext Paris market on May 21, 2026

Expected Paris trading resumption 3:30 p.m. Approximate local time for trading restart on May 21, 2026

Corresponding New York time 9:30 a.m. Approximate NY time when Euronext Paris trading is expected to resume

Key Terms

American Depositary Shares, pre-funded warrants, Global Offering, qualified investors, +1 more

5 terms

American Depositary Shares financial

"a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

pre-funded warrants financial

"an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Global Offering financial

"the “International Offering” and, together with the U.S. Offering, the “Global Offering”"

A global offering is when a company sells its shares or other securities to investors in multiple countries at the same time, combining new shares and sometimes existing ones. It matters to investors because it can change how many shares are available, affect the stock’s price and liquidity, and bring in capital or let insiders cash out—much like a concert releasing tickets worldwide at once, expanding the buyer pool and influencing demand and resale value.

qualified investors regulatory

"exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129"

Qualified investors are individuals or institutions that meet regulatory standards—such as a minimum income, net worth, or professional expertise—allowing them access to investment opportunities not open to the general public. Think of them as a financial "VIP" group: they can buy private deals, complex products, or early-stage securities that may offer higher returns but also carry greater risk and less public information, so their status matters because it changes what investments are available and what protections apply.

Regulation (EU) 2017/1129 regulatory

"within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended"

An EU law that sets uniform rules for the detailed disclosure document companies must give when offering securities to the public or listing them on markets. It matters to investors because it forces issuers to present a clear, standardized “label” of information—risks, business model, finances and terms—so you can compare offerings and spot missing or misleading claims. Think of it as a required ingredient list and instructions for financial products sold across the EU.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On May 21, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated May 21, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: May 21, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the “International Offering” and, together with the U.S. Offering, the “Global Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.

This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume on May 21, 2026, at approximately at approximately 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States), amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy + 33 06 70 33 49 50 carolinehardy@outlook.fr		Global – uncapped Communications Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Disclaimers

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Attachment

• 2026-05-21 -- NBTX -- Trading Halt -- FINAL (https://ml.globenewswire.com/Resource/Download/35f49f13-430c-4f6f-9aa1-b9da3b0a2ce9)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 6.5 KB